The results of that study suggest that the treatment is safe and has prospects for T1D treatment as insulin requirements in MSC-treated individuals did not change over the 12-month follow-up period, whereas insulin needs increased in placebo-treated individuals. This evidence concerns the gene INS and type 1 diabetes mellitus.